Breaking News
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Researchers find impact of neurobehavioral symptoms on employment in adults with TBI
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts |
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
September 24, 2018 - How a virus destabilizes the genome
September 24, 2018 - Old letters provide insight into Spanish flu pandemic horror
September 23, 2018 - Smart textile-based soft robotic exosuit helps wearers save energy and traverse difficult terrain
September 23, 2018 - New research hub to drive radical change in development and manufacturing of vaccines
September 23, 2018 - AHA: For Hispanics, Neighborhood May Be Key Factor in Heart Disease Risk
September 23, 2018 - Excessive airway nerves tied to more severe asthma symptoms, study finds
September 23, 2018 - Study highlights need to remain vigilant in maintaining key infection control processes
Low cost drug for serious bleeding may just save lives of moms after childbirth

Low cost drug for serious bleeding may just save lives of moms after childbirth

image_pdfDownload PDFimage_print

An affordable and extensively to be had drug may just save the lives of 1 in 3 moms who would another way bleed to demise after childbirth, in step with a significant learn about printed in The Lancet. The worldwide trial of 20,000 girls discovered that demise because of bleeding was once lowered via 31% if the remedy was once given inside 3 hours.

The drug, known as tranexamic acid (TXA), works via preventing blood clots from breaking down. The findings additionally display it lowered the desire for pressing surgical operation to keep watch over bleeding (laparotomy) via greater than a 3rd (36%).

Serious bleeding after childbirth (referred to as post-partum haemorrhage or PPH) is the main reason for maternal demise international. Greater than 100,000 girls globally die every 12 months from the situation, however this clot-stabilising drug has the possible to cut back the quantity considerably.

The WOMAN (International Maternal Antifibrinolytic) Trial recruited moms from 193 hospitals in 21 international locations, basically in Africa and Asia, but additionally in the United Kingdom and somewhere else. The London College of Hygiene & Tropical Drugs coordinated the trial. It was once funded via The Wellcome Accept as true with and UK Division of Well being during the Well being Innovation Problem Fund, and the Invoice & Melinda Gates Basis.

The effects display that of the ladies given tranexamic acid inside 3 hours, 89 died from bleeding when compared with 127 given placebo (along with usual care). The researchers discovered no unintended effects from the drug for both moms or small children. Those findings give you the first complete proof on the usage of tranexamic acid for post-partum haemorrhage and recommend it will have to be used as a frontline remedy.

Haleema Shakur, Affiliate Professor of Medical Trials on the London College of Hygiene & Tropical Drugs and Venture Director at the WOMAN Trial, stated:

We’ve got necessary proof that the early use of tranexamic acid can save girls’s lives and make sure extra youngsters develop up with a mom. It’s secure, inexpensive and simple to manage, and we are hoping that medical doctors will use it as early as conceivable following the onset of serious bleeding after childbirth.

Tranexamic acid was once invented within the 1960s via a Jap husband and spouse analysis staff, Shosuke and Utako Okamoto.

Ian Roberts, Professor of Medical Trials on the London College of Hygiene & Tropical Drugs, who co-led the learn about, stated:

The researchers who invented tranexamic acid greater than 50 years in the past was hoping it will cut back deaths from post-partum haemorrhage, however they couldn’t convince obstetricians on the time to habits an ordeal. Now we in the end have those effects that we are hoping can assist save girls’s lives world wide.

Virtually all the deaths from post-partum haemorrhage are in low- and middle-income international locations. Even though giving delivery in a well being facility will increase the risk of surviving post-partum haemorrhage, girls nonetheless die from the situation even inside hospitals.

Tim Knott, Senior Spouse in Inventions at Wellcome Accept as true with, stated:

Globally, serious bleeding in childbirth stays one of the most major reasons of maternal demise – with alarming numbers of girls loss of life in lots of low- and middle-income international locations. The WOMAN Trial staff undertook a vastly necessary and extremely bold learn about. Their paintings stands to make a essential distinction in combating girls loss of life after childbirth.

Whilst the WOMAN Trial discovered that tranexamic acid considerably lowered demise because of bleeding, it didn’t save you hysterectomy. The researchers say it is because in low- and middle-income international locations the place blood provides are restricted, a hysterectomy is every now and then performed instantly after the onset of very serious post-partum haemorrhage to avoid wasting the mummy’s existence. This implies there’s no time for tranexamic acid to have an impact.

The learn about builds on earlier analysis involving 20,000 trauma sufferers, which confirmed that tranexamic acid lowered deaths because of bleeding via virtually a 3rd if given inside 3 hours.

Present International Well being Group pointers, in response to the former trauma analysis, suggest the usage of tranexamic acid in post-partum haemorrhage as a next remedy possibility if uterotonics (medicine to urge contractions) fail to keep watch over the bleeding, or if the bleeding is considered because of trauma.

Publish-partum haemorrhage is outlined as a blood lack of greater than 500ml inside 24 hours of giving delivery.

Supply: kingdom/newsevents/information/2017/woman_trial_results.html

Tagged with:

About author

Related Articles